North-South Divide: Chemo-Immunotherapy Combination in Head and Neck Squamous Cell Cancer (HNSCC)

Affiliations

¹ Department of Clinical Oncology, University Hospital Southampton NHS Foundation Trust, Southampton, UK.
² Department of Clinical Oncology, Raigmore Hospital, Inverness, Scotland, UK.

Comment

I S Boon et al. Clin Oncol (R Coll Radiol). 2024 Jun.

. 2024 Jun;36(6):e169.

doi: 10.1016/j.clon.2024.03.006. Epub 2024 Mar 15.

¹ Department of Clinical Oncology, University Hospital Southampton NHS Foundation Trust, Southampton, UK.
² Department of Clinical Oncology, Raigmore Hospital, Inverness, Scotland, UK.

No abstract available

Comment on

The UK Divide: Does Having a Pembrolizumab-Chemotherapy Option in Head and Neck Cancer Matter? Real-world Experience of First-line Palliative Pembrolizumab Monotherapy and Pembrolizumab-Chemotherapy Combination in Scotland.
Thapa A, Cowell A, Peters A, Noble DJ, James A, Lamb C, Grose D, Vohra S, Schipani S, Mactier K, Mackenzie J, Srinivasan D, Laws K, Moleron R, Niblock P, Soh FY, Paterson C, Wilson C. Thapa A, et al. Clin Oncol (R Coll Radiol). 2024 May;36(5):287-299. doi: 10.1016/j.clon.2024.02.004. Epub 2024 Feb 12. Clin Oncol (R Coll Radiol). 2024. PMID: 38395634